Faruqi & Faruqi Investigates Cerevel Therapeutics Over Alleged Investor Deception A leading securities law firm is probing Cerevel Therapeutics, Bain Capital, and Pfizer for allegedly misleading investors during a 2023 stock offering. The lawsuit claims Bain profited from nonpublic information on AbbVie’s acquisition, while the proxy statement misrepresented the process. Investors have until June 3, 2025, to seek lead plaintiff status.12